Thermography in Surveillance of Ulcerative Colitis
Thermo
Prototype Study on Association Between Clinical, Laboratory and Thermographic Findings in Patients With Ulcerative Colitis
1 other identifier
observational
66
1 country
1
Brief Summary
Ulcerative colitis represents a chronic condition occurring in relapsing and remitting fashion with uncertain outcome and requires lifelong treatment with considerable side effects. Diagnostic methods currently in use, clinical (endoscopy), imaging (CT, MR) or laboratory (C - reactive protein, fecal calprotectin) give an insight into disease activity but are possibly associated with significant discomfort for the patient and / or increased risk of irradiation and potential allergic reactions on contrast agents. For that reason there is a need for a noninvasive, biologically inert method for evaluation of disease activity in inflammatory bowel disease (IBD). Thermography possesses most of these characteristics. The aim of this study is to find potential link between pathological thermographic signs and endoscopic findings, serum C reactive protein (CRP) and calprotectin in the stool of patients with active and extensive ulcerative colitis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2015
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 20, 2014
CompletedFirst Posted
Study publicly available on registry
May 29, 2014
CompletedStudy Start
First participant enrolled
January 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2018
CompletedJuly 17, 2018
July 1, 2018
3 years
May 20, 2014
July 13, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in abdominal surface temperatures in ulcerative colitis patients at 6 months
Patients will be treated with mesalamin, corticosteroids or biologic therapy according to disease status during 6 months. Abdominal temperatures (maximal, minimum and average temperatures measured in Celsius) recorded by a thermographic camera will be acquired at enrollment and after 6 months of therapy.
Six months
Secondary Outcomes (5)
Correlation of abdominal surface temperatures between ulcerative colitis patients and healthy volunteers.
Baseline and after 6 months
Correlation of abdominal surface temperature values with clinical markers of inflammation in ulcerative colitis.
Baseline and after 6 months
Correlation of abdominal surface temperature values with fecal markers of inflammation in ulcerative colitis.
Baseline and after 6 months
Correlation of abdominal surface temperature values with serum markers of inflammation in ulcerative colitis.
Baseline and after 6 months
Correlation of abdominal surface temperature values with endoscopic markers of inflammation in ulcerative colitis.
Baseline and after 6 months
Study Arms (2)
Ulcerative Colitis patients
30 patients with active ulcerative colitis will be put throe thermography and colonoscopy. Their stool will be tested for fecal calprotectin and their blood for CRP and other laboratory measures.
Healthy volunteers
30 healthy individuals matching sex and BMI to those of ulcerative colitis patients will be put throe thermography and have their stool tested for fecal calprotectin and their blood for CRP.
Interventions
Thermographic imaging of the patient's abdomen surface
Eligibility Criteria
The study population will be recruited among active ulcerative colitis patients hospitalized in University Hospital Dubrava. Healthy individuals matching sex and BMI to those of recruited ulcerative colitis patients.
You may qualify if:
- Endoscopic diagnosis of active extensive ulcerative colitis
- Stool Calprotectin \> 150 mcg/g
- CRP \> 5 mg/L
- Signed informed consent form
You may not qualify if:
- Inability to preform total colonoscopy
- Marked abdominal comorbidities
- Prior abdominal surgery
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital Dubrava
Zagreb, 10000, Croatia
Related Publications (3)
Banić M, et al. Thermography in patients with inflammatory bowel disease and colorectal cancer: evidence and review of the method. Periodicum biologorum 113(4): 439-444, 2011.
BACKGROUNDBožin, Tonći, et al.
BACKGROUNDBanić, Marko, et al.
BACKGROUND
Related Links
Biospecimen
Stool samples for fecal calprotectin concentration measurements.
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Marko Banić, MD, PhD
University Hospital Dubrava
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Gastroenterology Resident
Study Record Dates
First Submitted
May 20, 2014
First Posted
May 29, 2014
Study Start
January 1, 2015
Primary Completion
January 1, 2018
Study Completion
June 1, 2018
Last Updated
July 17, 2018
Record last verified: 2018-07
Data Sharing
- IPD Sharing
- Will not share